Stock listing

NASDAQ:IMA ImageneBio, Inc. Stock

Home listing (NASDAQ) of ImageneBio, Inc.

Follow ImageneBio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IMA

$3.92 USD +0.11 (+2.9%)

Close on Nov 20, 2026

Past year -45.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.79 – $4.04 USDNov 20, 2026
Volume
44,335 sharesNov 20, 2026
Market cap
$44.50M USDAt the close on Nov 20, 2026 · price × 11.35M shares outstanding
52-week range
$3.01 – $7.60 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$69,688 USDMedian day 11,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
ImageneBio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IMA · Home$3.92 USD+0.11 (+2.9%)44,335$4.04$4.04$3.785$3.81Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.92+0.11+2.9%$4.04$4.04$3.78544,335
$3.81-0.09-2.3%$3.98$3.98$3.785,286
$3.90+0.70+21.9%$3.20$4.10$3.00590,385
$3.20-0.27-7.8%$3.31$3.36$3.1323,166
$3.47+0.02+0.6%$3.50$3.579$3.3384,024
$3.45-0.27-7.3%$3.83$3.83$3.4410,628
$3.72-0.09-2.4%$3.81$3.85$3.713,869
$3.81-0.16-4.0%$4.12$4.12$3.6022,295
$3.97-0.135-3.3%$4.12$4.30$3.8914,659
$4.105-0.06-1.4%$4.04$4.26$4.041,401
$4.165+0.065+1.6%$4.00$4.165$4.0015,944
$4.10+0.08+2.0%$4.245$4.245$4.014,477
$4.02-0.07-1.7%$3.89$4.127$3.899,063
$4.09-0.01-0.2%$4.10$4.10$4.0457,608
$4.10+0.05+1.2%$4.05$4.21$4.055,671
$4.05-0.15-3.6%$4.15$4.15$4.044,998
$4.20+0.18+4.5%$4.02$4.45$4.0224,093
$4.02-0.03-0.7%$4.08$4.10$4.023,725
$4.05-0.17-4.0%$4.15$4.42$3.8832,900
$4.22+0.175+4.3%$3.98$4.30$3.987,869
$4.045-0.04-1.0%$4.08$4.115$4.0456,187
$4.085-0.045-1.1%$4.14$4.18$4.077,087
$4.13+0.13+3.2%$4.00$4.29$3.9822,004
$4.00-0.04-1.0%$4.00$4.13$3.996,063
$4.04+0.01+0.2%$4.15$4.15$4.009,800
$4.03-0.121-2.9%$4.26$4.26$3.98221,600
$4.151-0.089-2.1%$4.20$4.20$4.1420,800
$4.24-0.01-0.2%$4.16$4.25$4.05510,100
$4.25+0.01+0.2%$4.29$4.29$4.0028,100
$4.24-0.02-0.5%$4.17$4.31$3.908,100
$4.26-0.35-7.6%$4.48$4.48$4.0030,100
$4.61+0.01+0.2%$4.60$4.61$4.602,200
$4.60-0.10-2.1%$4.70$4.72$4.6013,700
$4.70+0.10+2.2%$4.602$4.73$4.6028,500
$4.60+0.02+0.4%$4.685$4.685$4.5577,800
$4.580.000.0%$4.60$4.67$4.5811,800
$4.580.000.0%$4.58$4.63$4.589,400
$4.58-0.06-1.3%$4.61$4.615$4.577,300
$4.64-0.08-1.7%$4.845$4.845$4.642,200
$4.72+0.06+1.3%$4.70$4.81$4.7017,800
$4.66-0.18-3.7%$4.82$4.82$4.653,700
$4.84-0.01-0.2%$4.95$4.975$4.811,500
$4.85+0.04+0.8%$4.765$5.02$4.7658,500
$4.81-0.08-1.6%$4.80$5.10$4.8023,900
$4.89-0.13-2.6%$5.18$5.24$4.6477,100
$5.02+0.09+1.8%$5.21$5.28$4.9922,800
$4.93+0.01+0.2%$5.175$5.18$4.8820,400
$4.92-0.08-1.6%$4.99$5.19$4.76214,200
$5.00-0.08-1.6%$5.22$5.39$4.99515,000
$5.08+0.075+1.5%$5.08$5.14$4.9258,000
$5.005-0.005-0.1%$5.02$5.30$4.9322,400
$5.01-0.04-0.8%$4.92$5.20$4.86520,900
$5.05+0.20+4.1%$4.98$5.285$4.8927,500
$4.85-0.035-0.7%$4.865$4.97$4.7315,500
$4.885-0.075-1.5%$4.89$4.94$4.8112,000
$4.96-0.06-1.2%$5.16$5.16$4.936,200
$5.02-0.08-1.6%$5.16$5.16$4.96512,500
$5.10-0.24-4.5%$5.48$5.54$4.9324,500
$5.34+0.01+0.2%$5.35$5.35$5.324,600
$5.33-0.10-1.8%$5.43$5.50$5.3317,400
$5.43-0.12-2.2%$5.659$5.659$5.3659,900
$5.55-0.07-1.2%$5.62$5.62$5.4416,800
$5.62+0.11+2.0%$5.68$5.70$5.5513,600
$5.51-0.10-1.8%$6.09$6.205$5.5119,900
$5.61-0.08-1.4%$5.75$5.75$5.613,500

Splits

1 split · NASDAQ:IMA · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
Ticker
NASDAQ:IMA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All ImageneBio, Inc. news

ImageneBio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 16 in all · newest Nov 9, 2026 · oldest 2025
Decks
5 decks · latest August 2026

Where ImageneBio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IMA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:IMABOATSUnited StatesUSD

Valuation

Price/book 0.3× against a median of 5.1×: the lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$80.79M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.52

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ImageneBio, Inc. · NASDAQ:IMAUS$44.50M−US$80.79Mn/an/an/a0.3×n/a0.0×0.52
MegaPro Biomedical Co., Ltd. · TPEX:6827US$45.95MUS$43.30Mn/an/an/a7.0×n/a0.0×n/a
SunBio, Inc. · KRX:067370US$45.82MUS$42.92M14.2×4.6×8.9×2.0×34.6%0.0×n/a
Apollomics Inc. · NASDAQ:APLMUS$45.28MUS$42.65Mn/a5.0×n/an/a−128.7%n/a1.02
Zelluna ASA · OSL:ZLNAUS$45.02MUS$38.83Mn/an/an/a5.1×n/a0.0×n/a
Oncoinvent ASA · OSL:ONCINUS$44.76MUS$33.80Mn/a14.3×n/a5.4×−673.1%0.0×n/a
Gain Therapeutics, Inc. · NASDAQ:GANXUS$44.50MUS$33.11Mn/an/an/a4.4×n/a0.0×1.60
Annovis Bio, Inc. · NYSE:ANVSUS$44.12MUS$41.30Mn/an/an/an/an/an/a2.53
Arch Biopartners, Inc. · TSXV:ARCHUS$44.06MUS$44.06Mn/an/an/an/an/an/a0.94
Spero Therapeutics, Inc. · NASDAQ:SPROUS$43.23M−US$63.10Mn/a−1.5×n/a55.4×−71.0%2.0×1.68
Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOXUS$43.15M−US$1.28Mn/an/an/a1.1×n/a0.3×n/a
Median of the othersUS$44.63MUS$40.06M14.2×4.8×8.9×5.1×−99.9%0.0×1.60

Forecasts

3 strong buy · 1 strong sell · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
18.00 USD · Analysts' mean
EPS, year to Dec 2026
-3.42 · 2 analysts

Team and board

Officers

OfficerRole
Kristin YaremaChief Executive Officer and Director
Kurinji PandiyanChief Strategy and Operations Officer
Renuka SivendranChief Technical Officer

Board

DirectorRole
Jonathan WangDirector
Kristin YaremaChief Executive Officer and Director
Weiguo SuDirector

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close−4.0%
Q2 2026Aug 5, 2026 · Before open+0.7%
Q1 2026May 7, 2026 · After close−10.5%
Q4 2025Mar 10, 2026+1.5%
Q3 2025Nov 12, 2025 · Before open−0.7%
Q2 2025Jul 24, 2025+3.6%
Q1 2025May 8, 2025+3.7%
Q4 2024Mar 6, 2025+6.7%
Q3 2024Nov 7, 2024+2.3%
Q2 2024Aug 9, 2024+0.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024+3.1%
Q4 2023Mar 12, 2024−3.4%
Q3 2023Nov 9, 2023−64.7%
Q2 2023Aug 10, 2023+2.4%
Q1 2023May 15, 2023−12.0%
Q4 2022Mar 14, 2023+0.7%
Q3 2022Nov 7, 2022+1.3%
Q2 2022Aug 11, 20220.0%
Q1 2022May 12, 2022−1.1%
Q4 2021Mar 17, 2022+26.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck24 slidesAugust 2026
Investor Presentation (November 2025)Investor deck25 slidesNov 19, 2025
Investor Presentation (July 2025)Investor deck36 slidesJul 29, 2025
Ikena Oncology — Merger or Acquisition (December 2024)Merger or acquisition27 slidesDec 23, 2024
Technical PresentationTechnical13 slides

Open Decks

Financings

RaiseDate
Private placement of pre-funded warrants
Announced: about US$30M · US$5.199 a share · Leerink Partners
Dealers: Leerink Partners (lead)
Buyers: Coastlands Capital; Trails Edge Capital Partners; Omega Funds; OrbiMed
Use of proceeds: Further development of IMG-007 in alopecia areata and late-stage development activities in atopic dermatitis
Apr 13, 2026
Private placement of common stock
Closed: US$75M raised
Buyers: Deep Track Capital; Foresite Capital; RTW Investments; BVF Partners L.P.; Blue Owl Healthcare Opportunities; Omega Funds; OrbiMed
Jul 25, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Ikena Oncology, Inc. Priced at US$16.00 a share on Mar 25, 2021.

Price
US$16.00 a share
Shares offered
7,812,500 shares of common stock
Offering size
US$125 million
Underwriters' option
Up to 1,171,875 more shares
Underwriters
Jefferies, Cowen, Credit Suisse, William Blair · In the order on the cover
Shares delivered
On or about Mar 30, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceJan 8, 2021
Filed publiclyMar 5, 2021
Amended onceMar 22, 2021
Shares registered with an exchangeMar 23, 2021
Declared effective by the SECMar 25, 2021
Final prospectus, with the priceMar 26, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Mar 26, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue800.0K3.50M9.16M15.6M31.0M9.19M13.8M990.0K
Cost of revenue1.03M1.53M1.02M64.3M47.1M44.8M24.9M39.0M
Gross profit-233.0K1.97M8.14M-48.7M-16.1M-35.7M-11.2M-38.0M
Research and development28.5M32.1M59.7M64.3M47.1M44.8M24.9M38.6M
Selling, general and administrative20.7M8.39M24.9M22.2M18.0M8.87M7.31M2.90M
Operating income-48.5M-37.0M-75.4M-70.9M-34.1M-44.5M-18.5M-40.9M
Depreciation and amortization400.0K1.10M1.02M751.0K544.0K300.0K243.0K422.0K
EBITDA-48.1M-35.9M-74.4M-70.2M-33.6M-44.2M-18.2M-40.5M
Income before tax-45.7M-36.6M-68.3M-68.8M-34.1M-44.3M-16.8M-40.9M
Income tax-350.0K13.0K-162.0K0071.1K
Net income-45.3M-36.6M-68.2M-68.8M-34.1M-44.3M-16.8M-40.9M
Earnings per share, basic-9.64-22.10-1.63-1.90-1.22-16.00-5.63-13.68
Earnings per share, diluted-9.64-22.10-1.63-1.90-1.22-16.00

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents94.5M12.1M119.9M59.9M232.2M162.5M82.1M18.2M
Short-term investments40.8M055.6M97.0M
Receivables1.30M
Current assets140.3M12.5M178.7M160.0M236.5M166.0M85.2M20.0M
Property, plant and equipment08.00K2.33M3.21M2.44M1.39M
Total assets153.0M15.9M192.1M172.3M247.9M168.4M86.0M20.7M
Accounts payable1.44M5.29M2.07M2.09M2.38M2.12M935.0K2.27M
Current liabilities11.2M17.2M14.2M21.5M27.2M28.3M24.3M3.82M
Total debt9.99M7.52M10.7M5.69M6.99M186.0K78.9M62.6M
Total liabilities19.8M17.4M22.3M25.3M40.0M63.5M147.4M66.5M
Shareholders' equity133.1M-160.6M-126.1M147.0M207.9M-101.0M-61.5M-45.8M
Shares outstanding12.5M48.3M48.3M36.3M36.0M3.10M2.99M2.99M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-47.8M-21.3M-79.7M-74.1M-60.3M-37.8M47.9M-11.6M
Capital spending00-414.0K-1.43M-1.76M-766.0K-316.0K-305.0K
Free cash flow-47.8M-46.0M-80.2M-75.5M-62.0M-38.6M47.6M-11.9M
Cash from investing-5.81M11.1M64.1M-99.3M-1.76M2.92M-316.0K11.0M
Cash from financing135.5M6.91M76.0M1.09M131.7M116.2M16.3M
Share buybacks-663.0K-57.0K
Change in cash82.4M-3.20M60.4M-172.3M69.7M81.3M63.9M-639.0K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
8-K · Current reportNov 9, 2026ResultsSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveAug 12, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 12, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 7, 2026Other filingsSEC
S-8 · Registration statement for employee plansAug 5, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
S-3 · Registration statementAug 5, 2026Offer documentSEC
POS AM · Amendment to an effective registrationAug 5, 2026Offer documentSEC
424B3 · ProspectusAug 5, 2026Offer documentSEC
S-3 · Registration statementAug 5, 2026Offer documentSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
3 · Initial statement of ownershipJul 28, 2026Insider tradeSEC
4 · Change in ownershipJul 28, 2026Insider tradeSEC
424B3 · ProspectusJul 23, 2026Offer documentSEC
8-K · Current reportJul 23, 2026Management or board changeSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
424B3 · ProspectusJun 29, 2026Offer documentSEC
8-K · Current reportJun 26, 2026Management or board changeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
424B3 · ProspectusJun 17, 2026Offer documentSEC
8-K · Current reportJun 17, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
424B3 · ProspectusMay 7, 2026Offer documentSEC
424B3 · ProspectusMay 7, 2026Offer documentSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 29, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 21, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeApr 21, 2026Big-stake noticeSEC
3 · Initial statement of ownershipApr 20, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
424B3 · ProspectusApr 13, 2026Offer documentSEC
8-K · Current reportApr 13, 2026Material contractSEC
EFFECT · Notice that a registration is effectiveApr 6, 2026Other filingsSEC
POS AM · Amendment to an effective registrationApr 2, 2026Offer documentSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
8-K · Current reportMar 17, 2026Management or board changeSEC
S-8 · Registration statement for employee plansMar 10, 2026Offer documentSEC
10-K · Annual reportMar 10, 2026Annual reportSEC
8-K · Current reportMar 10, 2026ResultsSEC
3 · Initial statement of ownershipFeb 20, 2026Insider tradeSEC
424B3 · ProspectusFeb 17, 2026Offer documentSEC
8-K · Current reportFeb 17, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 6, 2026Big-stake noticeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
424B3 · ProspectusDec 18, 2025Offer documentSEC
8-K · Current reportDec 18, 2025Management or board changeSEC
8-K · Current reportNov 19, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansNov 12, 2025Offer documentSEC
424B3 · ProspectusNov 12, 2025Offer documentSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
3 · Initial statement of ownershipNov 7, 2025Insider tradeSEC
424B3 · ProspectusNov 5, 2025Offer documentSEC
8-K · Current reportNov 5, 2025Management or board changeSEC
424B3 · ProspectusOct 30, 2025Offer documentSEC
8-K · Current reportOct 29, 2025Material contractSEC
8-K · Current reportOct 22, 2025Management or board changeSEC
8-K · Current reportOct 10, 2025Management or board changeSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 10, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveSep 16, 2025Other filingsSEC
CORRESP · Letter to the SECSep 11, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 11, 2025Other filingsSEC
S-1 · Registration statementSep 8, 2025Offer documentSEC
4 · Change in ownershipAug 15, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 15, 2025Insider tradeSEC
8-K/A · Current report, amendedAug 12, 2025Acquisition or disposalSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 7, 2025Insider tradeSEC
8-K · Current reportAug 5, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 4, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 4, 2025Big-stake noticeSEC
8-K · Current reportAug 1, 2025Management or board changeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 30, 2025Big-stake noticeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
4 · Change in ownershipJul 29, 2025Insider tradeSEC
4 · Change in ownershipJul 29, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 29, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 29, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
8-K · Current reportJul 29, 2025Acquisition or disposalSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 28, 2025Big-stake noticeSEC
8-K · Current reportJul 25, 2025Current reportSEC
10-Q · Quarterly reportJul 24, 2025Quarterly reportSEC
8-K · Current reportJul 24, 2025Current reportSEC
8-K · Current reportJul 22, 2025Current reportSEC
DJul 18, 2025Other filingsSEC
8-K · Current reportJul 16, 2025Management or board changeSEC
8-K · Current reportJul 15, 2025Management or board changeSEC
425Jul 11, 2025Other filingsSEC
8-K · Current reportJul 11, 2025Current reportSEC
425Jul 1, 2025Other filingsSEC
8-K · Current reportJul 1, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 18, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeJun 16, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJun 12, 2025Other filingsSEC
424B3 · ProspectusJun 11, 2025Offer documentSEC
CORRESP · Letter to the SECJun 10, 2025Other filingsSEC
S-4/A · Registration statement, amendedJun 9, 2025Offer documentSEC
CORRESP · Letter to the SECJun 9, 2025Other filingsSEC
UPLOAD · Letter from the SECJun 3, 2025Other filingsSEC
S-4/A · Registration statement, amendedMay 30, 2025Offer documentSEC
S-4/A · Registration statement, amendedMay 20, 2025Offer documentSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
CORRESP · Letter to the SECMay 7, 2025Other filingsSEC
S-4/A · Registration statement, amendedMay 7, 2025Offer documentSEC
UPLOAD · Letter from the SECMay 2, 2025Other filingsSEC
CORRESP · Letter to the SECApr 21, 2025Other filingsSEC
S-4/A · Registration statement, amendedApr 21, 2025Offer documentSEC
UPLOAD · Letter from the SECApr 14, 2025Other filingsSEC
S-4 · Registration statementMar 18, 2025Offer documentSEC
ARS · Annual report to shareholdersMar 6, 2025Annual reportSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
425Jan 10, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeDec 31, 2024Big-stake noticeSEC
425Dec 23, 2024Other filingsSEC
8-K · Current reportDec 23, 2024Material contractSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportJul 12, 2024Management or board changeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
8-K · Current reportJun 10, 2024Meeting outcomeSEC
8-K · Current reportMay 28, 2024Current reportSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
S-8 · Registration statement for employee plansMar 12, 2024Offer documentSEC
10-K · Annual reportMar 12, 2024Annual reportSEC
SC 13G/A · Big-stake notice, amendedMar 11, 2024Big-stake noticeSEC
4 · Change in ownershipMar 5, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 5, 2024Insider tradeSEC
8-K · Current reportFeb 21, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
8-K · Current reportJan 18, 2024ResultsSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
SC 13G · Big-stake noticeOct 19, 2023Big-stake noticeSEC
8-K · Current reportOct 11, 2023Meeting outcomeSEC
DEF 14A · Proxy statementSep 25, 2023Meeting noticeSEC
4/A · Change in ownership, amendedSep 21, 2023Insider tradeSEC
4/A · Change in ownership, amendedSep 21, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedSep 21, 2023Big-stake noticeSEC
PRE 14A · Preliminary proxy statementSep 15, 2023Meeting noticeSEC
4 · Change in ownershipSep 14, 2023Insider tradeSEC
4 · Change in ownershipSep 14, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedSep 14, 2023Big-stake noticeSEC
424B5 · ProspectusSep 12, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 11, 2023Other filingsSEC
CORRESP · Letter to the SECSep 6, 2023Other filingsSEC
DAug 18, 2023Other filingsSEC
S-3 · Registration statementAug 18, 2023Offer documentSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportAug 7, 2023Acquisition or disposalSEC
8-K · Current reportJun 30, 2023Current reportSEC
4 · Change in ownershipJun 13, 2023Insider tradeSEC

This page holds 200 of 339 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from ImageneBio, Inc.’s releases · as of Sep 30, 2026

Common shares
11,351,456
Fully diluted
11,351,456

Fully diluted

LineSharesAs of
Common shares11,351,456Sep 30, 2026

Share count over time

CountShares
Nov 22, 202611,351,456
Sep 30, 202612,456,281

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Blue Owl Capital Holdings LP1.14M9.1%US$5.2MSep 30, 2026
Bvf Inc1.11M8.9%US$5.08MSep 30, 2026
Trails Edge Capital Partners, LP1.09M8.8%US$5.01MSep 30, 2026
Orbimed Advisors LLC909K7.3%US$4.16MSep 30, 2026
Cable Car Capital, LP789K6.3%US$3.62MSep 30, 2026
Omega Fund Management, LLC455K3.7%US$2.09MSep 30, 2026
Vanguard372K3.0%US$1.7MSep 30, 2026
BML Capital Management, LLC201K1.6%US$919KSep 30, 2026
Monashee Investment Management LLC177K1.4%US$811KSep 30, 2026
BlackRock134K1.1%US$613KSep 30, 2026
All 35 holders
HolderSharesOf the companyValueAs of
Renaissance Technologies78,4950.63%US$360KSep 30, 2026
Geode Capital67,5370.54%US$309KSep 30, 2026
Adage Capital Partners Gp, L.L.C.66,6660.54%US$305KSep 30, 2026
Stonepine Capital Management, LLC57,6630.46%US$264KSep 30, 2026
NEA Management Company, LLC50,0050.40%US$229KSep 30, 2026
Nano Cap New Millennium Growth Fund L P50,0000.40%US$229KSep 30, 2026
Millennium40,3860.32%US$185KSep 30, 2026
HSBC34,2280.27%US$157KSep 30, 2026
Sofinnova Investments, Inc.31,8840.26%US$146KSep 30, 2026
Two Sigma20,9000.17%US$95,722Sep 30, 2026
Rangeley Capital, LLC20,0900.16%US$92,012Sep 30, 2026
Shay Capital LLC18,2050.15%US$83,379Sep 30, 2026
Aldebaran Capital, LLC17,7470.14%US$81,281Sep 30, 2026
Northern Trust11,2710.09%US$51,621Sep 30, 2026
Goldman Sachs10,9260.09%US$50,041Sep 30, 2026
Barclays10,7970.09%US$49,450Sep 30, 2026
Morgan Stanley9,1660.07%US$41,981Sep 30, 2026
UBS7,1630.06%US$32,807Sep 30, 2026
Tower Research Capital LLC (TRC)1,046<0.01%US$4,791Sep 30, 2026
Caitong International Asset Management Co., Ltd464<0.01%US$2,125Sep 30, 2026
Elequin Capital, LP385<0.01%US$1,763Sep 30, 2026
Fidelity360<0.01%US$1,649Sep 30, 2026
NewEdge Advisors, LLC160<0.01%US$732Sep 30, 2026
JPMorgan70<0.01%US$321Sep 30, 2026
BNP Paribas24<0.01%US$110Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund265K2.1%US$1.56MJun 30, 2026
Vanguard Extended Market Index Fund52,4670.42%US$310KJun 30, 2026
Fidelity Extended Market Index Fund31,6790.25%US$181KMay 31, 2026
iShares Micro-Cap ETF26,7070.21%US$158KJun 30, 2026
Fidelity Series Total Market Index Fund7,2990.06%US$41,604May 31, 2026
Fidelity Total Market Index Fund5,8210.05%US$33,180May 31, 2026
Fidelity Nasdaq Composite Index Fund4,2190.03%US$24,048May 31, 2026
Vanguard Balanced Index Fund3,2800.03%US$19,352Jun 30, 2026
1290 VT Micro Cap Portfolio1,7870.01%US$10,543Jun 30, 2026
Total Stock Market Index Trust434<0.01%US$2,561Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Lally Robert B
Officer: Principal Accounting Officer
Sale1,525USD 5.34US$8,144Jul 17, 2026
Lally Robert B
Officer: Principal Accounting Officer
Sale1,671USD 5.50US$9,191Jul 16, 2026

Big stakes

StakeStakeSharesDateFiling
BVF PARTNERS L P/IL9.90%1.13MJun 30, 2026Schedule 13G
Trails Edge Capital Partners, LP9.90%1.18MApr 14, 2026Schedule 13G
Blue Owl Capital Holdings LP9.11%1.14MSep 30, 2026Schedule 13G
Omega Fund VI, L.P.8.40%936KApr 14, 2026Schedule 13D
Funicular Funds, LP5.80%644KDec 29, 2025Schedule 13G
Atlas Venture Fund X, L.P.2.10%242KJul 25, 2025Schedule 13D
BML Investment Partners, L.P.1.90%216KJul 25, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jean-François Formela
Other companies: Korro Bio, Inc. (Co-Founder & Director · Since at least Nov 3, 2023); Translate Bio Inc (Director · Jun 27, 2018 – Sep 14, 2021 · Past); Spero Therapeutics, Inc. (Director · Nov 1, 2017 – Aug 17, 2021 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – Jun 14, 2022 · Past); Egalet Corporation (Director · Feb 5, 2014 – Feb 11, 2014 · Past); Oruka Therapeutics, Inc. (Director · Feb 10, 2012 – Oct 22, 2012 · Past); Horizon Pharma PLC (Director · Jul 28, 2011 – Mar 2, 2012 · Past)
Director · Mar 25, 2021 – Jun 7, 2024 · Past
David Bonita
Other companies: Windward Bio Group AG (Director · Since at least Nov 16, 2026); Third Harmonic Bio Inc. (Director · Since at least Aug 11, 2025); Prelude Therapeutics Incorporated (Director · Since at least Jun 12, 2025)
Director · Since at least Jul 25, 2025
Maria Koehler
Other companies: ARS Pharmaceuticals, Inc. (Director · Mar 12, 2021 – Jun 10, 2022 · Past); Repare Therapeutics Inc (EVP, CHIEF MEDICAL OFFICER · Jun 18, 2020 – Mar 12, 2025 · Past)
Director · Apr 15, 2021 – Jun 7, 2024 · Past
Erin Butler
Other companies: Armata Pharmaceuticals, Inc. (Vice President,Finance & Admin · Jul 1, 2022 – Jul 1, 2022 · Past)
Principal Accounting Officer · Since at least Jul 25, 2025
Jotin Marango
Other companies: Aptose Biosciences Inc (Senior VP, CFO, and CBO · Jun 3, 2019 – Jan 18, 2022 · Past)
Chief Financial Officer · Since at least Apr 25, 2022
Sergio L Santillana
Other companies: Merrimack Pharmaceuticals Inc (Chief Medical Officer · Jun 12, 2017 – Dec 11, 2018 · Past)
Chief Medical Officer · Mar 25, 2021 – Jan 3, 2023 · Past
Yanina Grant-Huerta
Other companies: Atara Biotherapeutics, Inc. (Chief Accounting Officer · Since at least May 18, 2026)
Chief Financial Officer · Since at least Aug 14, 2026
Jeffrey EcsedyChief Development Officer · Mar 25, 2021 – Feb 1, 2024 · Past
Jonathan WangDirector · Since at least Jul 25, 2025
Kristin YaremaChief Executive Officer and Director · Since at least Aug 17, 2026
All 19 people
PersonSeat
Kurinji PandiyanChief Strategy and Operations Officer · Since at least Nov 12, 2025
Mark ManfrediPresident & CEO, Director · Mar 25, 2021 – Feb 1, 2024 · Past
Matt RobbinsGeneral Counsel · Jul 7, 2026 – Nov 5, 2026 · Past
Maude TessierChief Business Officer · Mar 25, 2021 – Feb 2, 2022 · Past
Renuka SivendranChief Technical Officer · Since at least Nov 12, 2025
Robert B LallyPrincipal Accounting Officer · Since at least Jul 16, 2026
Stephen Hui WangDirector · Since at least Jul 25, 2025
Weiguo SuDirector · Since at least Nov 5, 2026
Yufang LuChief Medical Officer · Since at least Jul 25, 2025

Open People

Log in to ask 6ix AI your own questions about ImageneBio, Inc.